Powder: -20°C for 3 years | In solvent: -80°C for 1 year
WNK-IN-B is an inhibitor of Wnk signalling. WNK-IN-B is a cell-permeable diaminoacridine derivative that targets the CCT domain of SPAK and OSR1 via reversible binding. WNK-IN-B selectively suppress hypotonic shock-induced WNK signaling pathway activation in mpkDCT and MOVAS (100 µM) cultures without affecting p38 MAPK phosphorylation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,470.00 | |
50 mg | 6-8 weeks | $ 1,910.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | WNK-IN-B is an inhibitor of Wnk signalling. WNK-IN-B is a cell-permeable diaminoacridine derivative that targets the CCT domain of SPAK and OSR1 via reversible binding. WNK-IN-B selectively suppress hypotonic shock-induced WNK signaling pathway activation in mpkDCT and MOVAS (100 µM) cultures without affecting p38 MAPK phosphorylation. |
Targets&IC50 | WNK1:34.4 μM (IC50), WNK4:16 μM (IC50) |
Synonyms | WNK IN B, WNK-IN-B, Compound B |
Molecular Weight | 333.38 |
Formula | C20H19N3O2 |
CAS No. | 332922-63-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
STOCK2S-26016 332922-63-1 WNK IN B STOCK-2S-26016 WNK-IN-B STOCK2S26016 STOCK2S 26016 Compound B inhibitor inhibit